Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

Dapagliflozin; Empagliflozin; Heart failure

Detalles Bibliográficos
Autores: De Lorenzi, Andrea Beatriz, Kaplinsky, Edgardo, Rivera Zambrano, Marx, Tomás Chaume, Laia, Monell Rosas, Joan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/9650
Acceso en línea:https://hdl.handle.net/11351/9650
Access Level:acceso abierto
Palabra clave:Insuficiència cardíaca
Inhibidors de les glucosidases
Cor - Malalties
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Sodium-Glucose Transporter 2 Inhibitors
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure::Heart Failure, Systolic
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores del cotransportador de sodio-glucosa 2
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca::insuficiencia cardíaca sistólica
id ES_1ed0c97f4b1d9822e6d7f7d4e9ebb29a
oai_identifier_str oai:scientiasalut.gencat.cat:11351/9650
network_acronym_str ES
network_name_str España
repository_id_str
spelling Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fractionDe Lorenzi, Andrea BeatrizKaplinsky, EdgardoRivera Zambrano, MarxTomás Chaume, LaiaMonell Rosas, JoanInsuficiència cardíacaInhibidors de les glucosidasesCor - MalaltiesDISEASES::Cardiovascular Diseases::Heart Diseases::Heart FailureCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Sodium-Glucose Transporter 2 InhibitorsDISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure::Heart Failure, SystolicENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíacaCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores del cotransportador de sodio-glucosa 2ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca::insuficiencia cardíaca sistólicaDapagliflozin; Empagliflozin; Heart failureDapagliflozina; Empagliflozina; Atac de corDapagliflozina; Empagliflozina; Insuficiencia cardiacaThe role of sodium-glucose cotransporter 2 inhibitors (SLTG2i), developed initially as glucose-lowering agents, has represented a novelty in patients with heart failure (HF) and reduced ejection fraction (HFrEF) since dapagliflozin (DAPA-HF study) and empagliflozin (EMPEROR-Reduced study) were able to reduce morbidity and mortality in this setting regardless of the presence or absence of diabetes. In previous large clinical trials (EMPA-REG OUTCOME study, CANVAS, DECLARE-TIMI 58), SGLT2i have been shown to attenuate HF progression expressed by reducing the risk of HF hospitalizations in patients with type 2 diabetes mellitus mostly without HF at baseline. This benefit was then corroborated with positive results in HF outcomes (cardiovascular mortality and HF hospitalizations) in patients with HF with preserved ejection fraction (HFpEF) in the EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials. Several biological mechanisms apart from the glycosuria are attributed to these agents in this last context, including anti-inflammatory effects, reduction of fibrosis and apoptosis, improvement of myocardial metabolism, mitochondrial function optimization, and oxidative stress protection. Moreover, SGLT2i can also improve ventricular loading conditions by forcing diuresis and natriuresis, and by enhancing vascular and renal function. In addition, SGLT2i can reduce myocardial passive stiffness (diastolic function) by enforcing the phosphorylation of myofilament modulatory proteins. This article provided an overview of the main pathophysiological characteristics of HFpEF and of the diverse mechanisms of action of SGLT2i in this setting. The supporting clinical evidence of SGLT2i in HFpEF (EMPEROR-Preserved and DELIVER trials) is also reviewed. This article is part of the Emerging concepts in heart failure management and treatment Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment.BioExcel Publishing[De Lorenzi AB, Zambrano MR, Chaume LT, Rosas JM] Unitat de Cardiología, Hospital General de Granollers, Granollers, Spain. [Kaplinsky E] Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, SpainHospital General de Granollers202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/9650Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésDrugs in Context;12https://doi.org/10.7573/dic.2022-7-1Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/96502026-06-12T09:38:37Z
dc.title.none.fl_str_mv Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
title Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
spellingShingle Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
De Lorenzi, Andrea Beatriz
Insuficiència cardíaca
Inhibidors de les glucosidases
Cor - Malalties
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Sodium-Glucose Transporter 2 Inhibitors
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure::Heart Failure, Systolic
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores del cotransportador de sodio-glucosa 2
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca::insuficiencia cardíaca sistólica
title_short Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
title_full Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
title_fullStr Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
title_full_unstemmed Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
title_sort Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
dc.creator.none.fl_str_mv De Lorenzi, Andrea Beatriz
Kaplinsky, Edgardo
Rivera Zambrano, Marx
Tomás Chaume, Laia
Monell Rosas, Joan
author De Lorenzi, Andrea Beatriz
author_facet De Lorenzi, Andrea Beatriz
Kaplinsky, Edgardo
Rivera Zambrano, Marx
Tomás Chaume, Laia
Monell Rosas, Joan
author_role author
author2 Kaplinsky, Edgardo
Rivera Zambrano, Marx
Tomás Chaume, Laia
Monell Rosas, Joan
author2_role author
author
author
author
dc.contributor.none.fl_str_mv [De Lorenzi AB, Zambrano MR, Chaume LT, Rosas JM] Unitat de Cardiología, Hospital General de Granollers, Granollers, Spain. [Kaplinsky E] Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, Spain
Hospital General de Granollers
dc.subject.none.fl_str_mv Insuficiència cardíaca
Inhibidors de les glucosidases
Cor - Malalties
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Sodium-Glucose Transporter 2 Inhibitors
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure::Heart Failure, Systolic
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores del cotransportador de sodio-glucosa 2
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca::insuficiencia cardíaca sistólica
topic Insuficiència cardíaca
Inhibidors de les glucosidases
Cor - Malalties
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Sodium-Glucose Transporter 2 Inhibitors
DISEASES::Cardiovascular Diseases::Heart Diseases::Heart Failure::Heart Failure, Systolic
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores del cotransportador de sodio-glucosa 2
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca::insuficiencia cardíaca sistólica
description Dapagliflozin; Empagliflozin; Heart failure
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/9650
url https://hdl.handle.net/11351/9650
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Drugs in Context;12
https://doi.org/10.7573/dic.2022-7-1
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioExcel Publishing
publisher.none.fl_str_mv BioExcel Publishing
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404363141677056
score 15,811543

Similares en LA Referencia